Repligen Corporation (RGEN)

NASDAQ: RGEN · IEX Real-Time Price · USD
+0.19 (0.11%)
At close: Jun 2, 2023, 4:00 PM
+0.74 (0.44%)
After-hours: Jun 2, 2023, 4:58 PM EDT

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber.

Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.

The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.

Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation
Repligen logo
Country United States
Founded 1981
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 2,025
CEO Anthony J. Hunt

Contact Details

41 Seyon Street, Building 1, Suite 100
Waltham, Massachusetts 02453
United States
Phone (781) 449-9560

Stock Details

Ticker Symbol RGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000730272
CUSIP Number 759916109
ISIN Number US7599161095
Employer ID 04-2729386
SIC Code 2836

Key Executives

Name Position
Anthony J. Hunt President, Chief Executive Officer and Director
Jon K. Snodgres Chief Financial Officer
James R. Bylund Chief Operating Officer
Christine Gebski Senior Vice President of Filtration and Chromatography
Ralf Kuriyel Senior Vice President of Research & Development
Sondra S. Newman Global Head of Investor Relations
Kimberly Cornwell Global Head of Legal and General Counsel
Stephen Tingley Vice President and Head of Global Sales
Rachel Goodrich Vice President of Marketing
Craig Harrison Senior Vice President of Process Analytics

Latest SEC Filings

Date Type Title
May 22, 2023 8-K Current Report
May 2, 2023 10-Q Quarterly Report
May 2, 2023 8-K Current Report
Apr 18, 2023 8-K Current Report
Apr 12, 2023 8-K Current Report
Apr 11, 2023 ARS Filing
Apr 11, 2023 DEF 14A Other definitive proxy statements
Mar 24, 2023 PRE 14A Other preliminary proxy statements
Feb 22, 2023 10-K Annual Report
Feb 22, 2023 8-K Current Report